The NEI reports that diabetic retinopathy affects approximately 7.7 million Americans — making it the leading cause of new blindness in working-age adults in the U.S. If you or someone you care for has diabetes, understanding the treatment costs isn’t just useful. It’s necessary.
The cost range is wide: $300 per session for older laser treatments up to $4,000+ per eye for a single anti-VEGF injection visit. And since most treatments repeat monthly or quarterly for years, the total annual burden frequently runs $3,000–$20,000 — even with good insurance.
The Three Main Treatment Approaches
1. Laser Photocoagulation
The older treatment approach uses a laser to seal leaking blood vessels in the retina (focal/grid laser for diabetic macular edema) or to shrink the peripheral retina to reduce the drive for new vessel growth (panretinal photocoagulation, or PRP, for proliferative diabetic retinopathy).
Laser is a one-time or limited-session treatment — most patients need 1–3 sessions. It doesn’t typically restore vision but stabilizes it and prevents further loss. Facility fees, physician fees, and anesthesia are all separate billing items.
2. Anti-VEGF Injections
The current first-line treatment for diabetic macular edema (the most vision-threatening form of diabetic retinopathy) involves injecting medications directly into the vitreous cavity of the eye to block VEGF — the protein that drives abnormal vessel leakage and growth.
Three anti-VEGF drugs dominate practice:
- Avastin (bevacizumab): ~$60–$100 per dose; off-label use
- Eylea (aflibercept): ~$1,800–$2,100 per dose; FDA-approved for DR
- Lucentis (ranibizumab): ~$1,900–$2,300 per dose; FDA-approved for DR
The drug cost is separate from the administration fee (physician work) and facility fee. Total per-session billing can reach $2,500–$4,000 for a branded anti-VEGF injection at a hospital-based retina practice.
3. Vitrectomy for Advanced Disease
When diabetic retinopathy progresses to traction retinal detachment or non-clearing vitreous hemorrhage, surgery is required. Vitrectomy removes the gel from the inside of the eye and peels fibrous membranes off the retina. It’s the most expensive intervention.
Cost Breakdown by Treatment Type
| Treatment | Cost Per Session | Sessions/Year (Typical) | Annual Cost Estimate |
|---|---|---|---|
| Focal/grid laser (diabetic macular edema) | $800–$1,500 | 1–3 initially, then rare | $800–$4,500 first year |
| Panretinal photocoagulation (PRP, proliferative DR) | $1,000–$2,000 | 2–3 sessions initially | $2,000–$6,000 |
| Anti-VEGF injection — Avastin (off-label) | $400–$700 total | 6–12 | $2,400–$8,400 |
| Anti-VEGF injection — Eylea or Lucentis | $2,500–$4,000 total | 6–12 | $15,000–$48,000 (pre-insurance) |
| Vitrectomy (advanced proliferative DR) | $7,000–$15,000 | 1 per eye (one-time) | — |
| OCT imaging (monitoring) | $100–$300 | 4–12 | $400–$3,600 |
Anti-VEGF drug costs in the table above are the billed amounts before insurance adjustments. Your actual out-of-pocket is dramatically lower with good medical insurance. Medicare pays about 80% of the Medicare-approved amount for anti-VEGF injections administered in a physician’s office. The key phrase there is “physician’s office” — the same injection at a hospital outpatient department triggers a facility fee that can add $800–$1,500 to each visit. Ask your retina specialist whether their injection clinic is office-based or hospital-affiliated before you start treatment.
Insurance Coverage: Medical Benefits, Not Vision Benefits
This distinction matters more than almost anything else on this page. Diabetic retinopathy treatment is a medical claim:
Medicare Part B: Covers anti-VEGF injections, laser procedures, and vitrectomy. You pay the Part B deductible ($257 in 2026) plus 20% coinsurance. For a patient receiving 10 Eylea injections annually at $2,000 Medicare-approved rate each, the 20% coinsurance is $4,000/year — real money, but a fraction of the total cost. Medicare Advantage plans vary; some have lower coinsurance for Part B drugs.
Private insurance: Most cover diabetic retinopathy treatments as Part B-equivalent benefits, often requiring prior authorization for branded anti-VEGF drugs. Avastin (off-label) may require showing it’s medically appropriate; branded drugs require showing Avastin failed or is contraindicated.
Uninsured: The full retail drug cost plus facility fees. At $2,500–$4,000 per injection and monthly injection schedules, an uninsured patient’s annual anti-VEGF costs can exceed $30,000. Manufacturer patient assistance programs for Eylea and Lucentis exist — search the manufacturer websites for eligibility requirements.
The Real Cost: It’s Annual, Not One-Time
That’s the number most cost guides miss. A single vitrectomy is a one-time cost of $7,000–$15,000 — scary but finite. Anti-VEGF injections for diabetic macular edema are ongoing. The NEI’s DRCR Retina Network data shows that many patients require injections for years, not months.
Four practical strategies that work within the standard of care:
Ask about Avastin. If your retina specialist hasn’t mentioned bevacizumab (Avastin) as an off-label option, ask. NEI’s Protocol T trial showed equivalent outcomes to Lucentis and Eylea for most patients. At $60–$100/dose versus $1,800–$2,300, the math is significant.
Use a physician’s office, not a hospital clinic. Anti-VEGF injections done in the office don’t trigger a hospital facility fee. The same physician working in a hospital-affiliated setting bills facility fees that can add $800+ per visit.
Maximize diabetes control. The AAO’s clinical guidelines are explicit: better glycemic control and blood pressure control significantly slow retinopathy progression and can extend the interval between injections for patients already in treatment.
Enroll in co-pay assistance programs. Regeneron (Eylea) and Genentech (Lucentis) both offer commercial insurance co-pay assistance that caps your annual cost. Not available for Medicare patients, but valuable for commercial plan members.
The Bottom Line
Diabetic retinopathy treatment is expensive, ongoing, and non-optional if you want to keep your vision. Annual costs with branded anti-VEGF injections run $3,000–$10,000 out-of-pocket even with decent insurance. The 7.7 million Americans already affected — and the millions more who’ll develop it as the diabetes epidemic continues — face this financial reality alongside the clinical one.
The two best cost-reduction moves: ask your retina specialist about Avastin (equivalent outcomes, 95% lower drug cost), and control your diabetes aggressively to extend treatment intervals. Everything else is secondary.
Cost data based on NEI epidemiological reports on diabetic retinopathy prevalence, DRCR Retina Network clinical trial data on anti-VEGF injection frequency, and Medicare reimbursement schedules for anti-VEGF procedures. Drug pricing reflects 2025–2026 Average Sales Price data.
Frequently Asked Questions
Health insurance — not vision insurance. Diabetic retinopathy is a medical condition caused by diabetes, so treatment (anti-VEGF injections, laser photocoagulation, vitrectomy) is billed as a medical claim under your health insurance plan. Your vision plan (VSP, EyeMed, etc.) won't cover it. Medicare Part B covers anti-VEGF injections and laser procedures with the standard 20% coinsurance after the deductible. Make sure your retina specialist's billing team files under medical benefits to avoid claim denials.
Initially, the standard protocol for diabetic macular edema is monthly injections for 3–5 months, then extending intervals based on treatment response. Many patients move to every 6–8 weeks after stabilizing, while others need monthly injections indefinitely. The NEI's DRCR Retina Network has published data showing that about 40% of patients with center-involving diabetic macular edema can eventually extend to quarterly visits, but roughly a third require ongoing monthly injections to maintain vision gains. Over a 2-year treatment course, most patients receive 10–18 injections total.
Bevacizumab (Avastin), used off-label, costs about $60–$100 per injection for the drug itself — versus $1,900–$2,300 for Lucentis (ranibizumab) and $1,800–$2,100 for Eylea (aflibercept). The NEI-funded Protocol T trial found Avastin was equivalent in efficacy to Lucentis and Eylea for most patients with diabetic macular edema. Many retina specialists offer it for cost-sensitive or uninsured patients. However, because it's off-label, some insurers require a prior authorization for approved drugs first, and academic centers sometimes have institutional policies against off-label compounded injectables.